Q2 2026 saw 12% sales growth excluding currency effects, with EBIT up 22% and margins improving. Pediatrics and Adult Health segments both delivered strong growth, while EMEA and Americas outperformed and APAC declined. Cash flow was impacted by higher working capital.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.